Olaparib and TRAIL exhibited a potent synergistic antineoplastic activity with CI values below 0.7 (Figure 1) in CAPAN1, CAPAN2, and PaTu-S pancreatic cancer lines. The gene discussed is TNFSF10; the disease is familial pancreatic carcinoma.